177Lu FC705
Alternative Names: 177Lu-FC705; [177Lu]-Ludotadipep; Lu-177 LudotadipepLatest Information Update: 22 Dec 2022
At a glance
- Originator FutureChem
- Class Antineoplastics; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Prostate cancer
Most Recent Events
- 30 Oct 2022 Phase-II clinical trials in Prostate cancer (Hormone refractory, Metastatic disease) in South Korea (IV) (NCT05579184)
- 13 Oct 2022 FutureChem plans a phase II LUCIDA_2 trial for Prostate cancer (In Metastatic disease, Hormone refractory)(Parenteral) in South Korea (NCT05579184)
- 01 Sep 2022 Phase-I/II clinical trials in Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT05458544)